Laboratory Corporation of America Holdings (NYSE:LH) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities research analysts have also issued reports about the company. Barclays PLC set a $165.00 price objective on Laboratory Corporation of America Holdings and gave the stock a “buy” rating in a research note on Saturday, February 18th. Credit Suisse Group restated a “buy” rating and issued a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a research note on Sunday, May 28th. Jefferies Group LLC restated a “hold” rating and issued a $159.00 price objective on shares of Laboratory Corporation of America Holdings in a research note on Friday, February 17th. Zacks Investment Research lowered Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Finally, ValuEngine lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $155.75.

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Shares of Laboratory Corporation of America Holdings (LH) traded up 0.26% during trading on Friday, hitting $140.77. The stock had a trading volume of 764,011 shares. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $146.63. The firm has a market capitalization of $14.40 billion, a P/E ratio of 19.34 and a beta of 0.99. The stock’s 50-day moving average price is $140.42 and its 200 day moving average price is $137.36.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Tuesday, April 25th. The medical research company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.19 by $0.03. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.41 billion. Laboratory Corporation of America Holdings had a return on equity of 16.99% and a net margin of 7.76%. Laboratory Corporation of America Holdings’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. On average, analysts anticipate that Laboratory Corporation of America Holdings will post $9.44 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Financial Market News and is owned by of Financial Market News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.financial-market-news.com/2017/06/17/laboratory-corporation-of-america-holdings-lh-upgraded-at-bidaskclub.html.

In other Laboratory Corporation of America Holdings news, SVP Lance Berberian sold 3,613 shares of the stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the transaction, the senior vice president now owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean-Luc Belingard sold 992 shares of the stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $142.19, for a total transaction of $141,052.48. Following the transaction, the director now directly owns 32,935 shares of the company’s stock, valued at approximately $4,683,027.65. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Endurance Wealth Management Inc. increased its position in Laboratory Corporation of America Holdings by 0.7% in the first quarter. Endurance Wealth Management Inc. now owns 1,510 shares of the medical research company’s stock valued at $217,000 after buying an additional 10 shares during the period. Oppenheimer & Co. Inc. increased its position in Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock valued at $346,000 after buying an additional 15 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in Laboratory Corporation of America Holdings by 0.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock valued at $594,000 after buying an additional 31 shares during the period. Intrust Bank NA increased its position in Laboratory Corporation of America Holdings by 1.1% in the first quarter. Intrust Bank NA now owns 4,065 shares of the medical research company’s stock valued at $583,000 after buying an additional 43 shares during the period. Finally, Mason Street Advisors LLC increased its position in Laboratory Corporation of America Holdings by 0.3% in the first quarter. Mason Street Advisors LLC now owns 14,137 shares of the medical research company’s stock valued at $2,028,000 after buying an additional 47 shares during the period. 92.56% of the stock is owned by institutional investors and hedge funds.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.